How Bigfoot Biomedical wants to disrupt diabetes care

Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin

Medtech stories we missed this week: July 14, 2017

From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief

Here are the top 5 medtech stories of mid-2017

The middle of 2017 is shaping up to be a continued whirlwind of activity for medtech. FDA is getting used to its new leadership but is facing a continued lack of clarity on user fees and UDIs. Industry is seeing a deeper consolidation in medical supplies, exemplified in Cardinal Health’s purchase of patient recovery supplies from

Pages: 1 2 3 4 5 6

Analysis: Here’s why medtech should feel optimistic about 2017

Uncertainty continues to swirl around the new Trump administration, but there is a lot to be excited about in the medical device industry these days, especially when it comes to cardiology and diabetes treatment. Medtech companies are performing well. More than 80% of the world’s 100 largest medical device companies saw their stock values increase

Hydrogel tech boosts success of transplanted insulin-producing cells

A hydrogel material embedded with a protein to improve blood vessel growth may boost the success rate of transplanting insulin-producing islet cells into patients with Type I diabetes, according to a preclinical study published in the journal Science Advances.  In the newly-published work, supported by the National Institutes of Health and the Juvenile Diabetes Research Foundation,

RxFunction device helps diabetics walk again

Patients who have peripheral neuropathy as a result of diabetes have shown improvement in their gait and balance using RxFunction’s new wearable sensory prosthesis, according to a new study. A research study from Wingate University has tested the long-term benefits of using wearable technology company RxFunction’s Walkasins in people who have peripheral neuropathy. “These exciting

9 diabetes breakthroughs you need to know

Diabetes is a disease that affects the body’s ability to produce and respond to insulin. About 29.1 million people have diabetes in the U.S, according to the Centers for Disease Control and Prevention. Of that number, 8.1 million go undiagnosed. One of the most popular breakthroughs in diabetes research has been the artificial pancreas, which

Pages: 1 2 3 4 5 6 7 8 9 10

Artificial pancreas: These companies are racing to make one

Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in our newest Medical Design & Outsourcing video. (And for a deeper dive, check out our recent roundup of companies in the

10 innovative diagnostic tests to combat diseases

This is an exciting time for medical diagnostics, with recent innovations allowing for faster disease diagnosis than ever before. From cancer to diabetes to heart disease, here are 10 diagnostic tests that could change the game when it comes to catching diseases earlier. Next >> [Want to stay more on top of MDO content? Subscribe to our

Pages: 1 2 3 4 5 6 7 8 9 10 11

Abbott lands French reimbursement win for FreeStyle Libre glucose monitor

Abbott (NYSE:ABT) said today it won national reimbursement from the French Health ministry for its FreeStyle Libre wearable glucose monitor. The FreeStyle Libre is designed to monitor glucose through a sensor worn on the back of the upper arm for 2 weeks, without the need for the finger prick calibration required by continuous glucose monitoring

Medtech stories we missed this week: May 5, 2017

From Biomerics’s $38.5 million expansion in Salt Lake City to new study results and partnerships, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Biomerics opening new corporate HQ Biomerics announced in a May 1 press release that it is moving its corporate headquarters in Salt Lake City. The

How deep learning algorithms could detect diabetic eye disease

Researchers at the Byers Eye Institute at Stanford University believe deep learning algorithms, a form of artificial intelligence, hold the key to detecting diabetic retinopathy and averting blindness in patients. Diabetic retinopathy damages the blood vessels at the back of the eye and is the leading cause of preventable blindness globally. Up to 45% of

Tandem misses on Q1 earnings, beats rev estimates

Shares in Tandem Diabetes (NSDQ:TNDM) fell today after the medical device maker missed earnings expectations on Wall Street with its 1st quarter results, but beat revenue estimates. The San Diego-based company posted losses of -$23.8 million, or -75¢ per share, on sales of $18.9 million for the 3 months ended March 31, for bottom-line loss of -13.9%

This contact lenses breakthrough could enable glucose monitoring

Biosensing contact lenses may not be able to self-heal like “The Terminator,” but they could measure blood glucose and detect other signs of disease in the future. Oregon State University researchers are set to present a study that suggests transparent biosensors that are embedded into contact lenses could provide insight for doctors and patients without

7 companies in the race to make an artificial pancreas

Over 50 years ago, scientists discovered the ability to externally control blood glucose regulation for individuals with type 1 diabetes. Since then, researchers in the field of diabetes management have dreamt of creating a closed-loop system – a combined glucose sensor, control algorithm and insulin infusion device – to effectively act as an “artificial pancreas”

Pages: 1 2 3 4 5 6 7 8 9